( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



*Dr. Mudassar Saeed Pansota (MS Urology), Dr. Mubasher Saeed Pansota, Dr. Hafiz Muhammad Tariq (FCPS), Dr. Muhammad Burhan Barkat (MS Urology), Dr. Muhammad Shahzad Saleem (FCPS) and Dr. Mumtaz Rasool (FCPS)


Introduction: Until now, the problem of treatment for OAB still remains challenging. Thus, the introduction of totally new drug mirabegron, which is a b3-adrenoreceptor agonist, has turned out to be much in demand among specialists engaged in OAB. In clinical practice, most OAB patients are initiated on an antimuscarinic, which is escalated to a higher dose or switched to an alternative antimuscarinic or the b3-adrenoceptor agonist, mirabegron. Objectives: To compare the efficacy of combination of mirabegron and solifenacin with mirabegron alone for overactive bladder in women. Materials & Methods: A total of 480 women having overactive bladder, 20 to 50 years of age were included. Patients with UTI, pregnancy, bladder stone, pelvic malignancy, spinal injury, multiple sclerosis, parkinson disease, diabetic neuropathy were excluded. Patients in group A took mirabegron 25mg + solifenacin 5 mg once daily for 12 weeks and in group B, patients took mirabegron 25 mg once daily for 12 weeks. Urinary incontinence was assessed at baseline and after 12 weeks of treatment on the base of history. OABS score at baseline and after 12 weeks of treatment. Patients were followed for 12 weeks by taking patient’s contact number. Efficacy was assessed as per operational definition after 12 weeks of treatment. Results: Mean OABS score at baseline and after 12 weeks in group A was 10.33 ± 3.12 and 4.43 ± 1.32 and in group B was 10.13 ± 2.98 and 6.87 ± 2.76 respectively. Efficacy of Group A (combination of mirabegron and solifenacin) was seen in 143 (59.58%) patients while in Group B (mirabegron alone) was seen in 117 (48.75%) patients with p-value of 0.017. Conclusion: This study concluded that combination of mirabegron and solifenacin is better than the mirabegron alone for management of overactive bladder in women.

Keywords: overactive bladder, mirabegron, solifenacin.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 June 2024 Issue has been Published, Kindly check it on


    JUNE 2024 issue has been successfully launched on JUNE 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia